Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Open access
Rosenfeld, Margaret, Wainwright, Claire E, Higgins, Mark, Wang, Linda T, McKee, Charlotte, Campbell, Daniel, Tian, Simon, Schneider, Jennifer, Cunningham, Steve, Davies, Jane C, Rosenfeld, Margaret, Wainwright, Claire E., Higgins, Mark, Wang, Linda T., McKee, Charlotte, Campbell, Daniel, Tian, Simon, Schneider, Jennifer, Cunningham, Steve, Davies, Jane C., Harris, William, Mogayzel, Peter, McCoy, Karen, Milla, Carlos, Rubenstein, Ronald, Walker, Seth, Black, Philip, Montgomery, Gregory, McColley, Susanna, Hiatt, Peter, Sawicki, Gregory, Rock, Michael, Aurora, Paul, Ratjen, Felix, Maitra, Anirban, Ives, Andrew, Gaillard, Erol, McNalley, Paul, Selvadurai, Hiranjan, Robinson, Philip · 2018 · The Lancet Respiratory Medicine

Abstract

SUMMARY Background: Ivacaftor is generally safe and effective in patients 2 years and older with cystic fibrosis (CF) and specific CFTR mutations. We evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of ivacaftor in children aged 12 to <24 months. Methods: This phase 3, single-arm, two-part, multicenter, multinational study (ARRIVAL) enrolled children 12 to <24 months with a confirmed diagnosis of CF and a CFTR gating mutation on at least one allele. Children received oral ivacaftor 50 mg (weight 7 to <14 kg) or 75 mg (weight ≥14 to <25 kg) every 12 hours for 4 days in part A (to assess short-term safety and PK) and 24 weeks in part B (to assess safety and PD and explore efficacy). Primary endpoints were PK (part A) and safety (A and B); analyses included all children who received ≥1 dose of ivacaftor. Secondary endpoints were PK and absolute change from baseline at week 24 in sweat chloride. Tertiary endpoints included absolute change from baseline at week 24 in growth parameters and markers of pancreatic function. Safety analyses in parts A and B were performed on all children dosed; PD and efficacy analyses in part B were performed on all children enrolled and dosed. Final data for children aged 12 to <24 months were collected from August 2016 to November 2017; ARRIVAL is ongoing for those aged <12 months. This study is registered with ClinicalTrials.gov, number NCT02725567. Findings: Seven children enrolled in part A, all of whom completed the 4-day treatment period and one of whom enrolled in part B. Nineteen children enrolled in part B, 18 of whom completed the 24-week treatment period. All patients received at least one dose of ivacaftor. PK results suggested that ivacaftor exposures were similar to those reported in older children and adults. Most adverse events (AEs) were typical for children with CF. The most common AE in part B was cough (in 14 [73·7%] of 19 children). Two children had four serious AEs; one (constipation) was considered to be possibly related to ivacaftor. Five (27·8%) of 18 children had transaminase elevations >3 × upper limit of normal (ULN) and remained on ivacaftor. Of these, two children had transaminase elevations >8 × ULN; both had concurrent infections and successfully resumed treatment after interruption. No children discontinued because of AEs or any safety findings. At week 24, mean (standard deviation) absolute change from baseline in sweat chloride was −73·5 (17·5) mmol/L. Growth parameters were normal at baseline and were generally maintained during treatment. There was an increase in fecal elastase-1 and a decrease in immunoreactive trypsinogen (IRT). Mean serum lipase and amylase were elevated at baseline and rapidly decreased with ivacaftor Interpretation: Ivacaftor at doses of 50 mg or 75 mg every 12 hours was generally safe and well tolerated in children 12 to <24 months with CF and a CFTR gating mutation for up to 24 weeks. Substantial improvements were observed in sweat chloride, and growth measures were generally well maintained. Reductions in lipase and amylase, a new observation, along with improvements in fecal elastase-1 and IRT, suggest ivacaftor could potentially preserve pancreatic function if initiated early in life. Funding: Vertex Pharmaceuticals Incorporated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(18)30202-9

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 273

Metadata

Authors
Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Harris, W., Mogayzel, P., McCoy, K., Milla, C., Rubenstein, R., Walker, S., Black, P., Montgomery, G., McColley, S., Hiatt, P., Sawicki, G., Rock, M., Aurora, P., Ratjen, F., Maitra, A., Ives, A., Gaillard, E., McNalley, P., Selvadurai, H., & Robinson, P.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2018-07
Volume
6
Issue
7
Pages
545-553
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2805157317
Cited by
273
References
22
FWCI
20.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30202-9
The paper
Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., . . . Robinson, P. (2018). Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30202-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.